Cholecystokinin-8 vs Nafarelin

Head-to-head comparison of Cholecystokinin-8 (Cholecystokinin (sulfated C-terminal octapeptide, CCK-8)) and Nafarelin (Nafarelin acetate) — benefits, dosing, side effects, research data, and where to buy.

Research Score

PropertyCholecystokinin-8Nafarelin
CategoryEndocrine PeptidesSexual Health
Full NameCholecystokinin (sulfated C-terminal octapeptide, CCK-8)Nafarelin acetate
Molecular Weight1143.2 Da1321.47 Da
Half-Life1-2 min~2-4 hours
Amino AcidsDY(SO3H)MGWMDF-NH210
Typical Dosephysiologic low-picomolar-nanomolar range|research-dependent200 mcg intranasal twice daily
Routeendogenous secretion|research IV/SCIntranasal
Purity≥98%≥98%
Studies Count97220
Research StatusEndogenousClinical

Cholecystokinin-8 Benefits

  • gallbladder contraction
  • pancreatic enzyme release
  • satiety signaling

Nafarelin Benefits

  • pituitary suppression
  • cycle scheduling
  • endometriosis-related reproductive care
  • controlled hormone modulation

Cholecystokinin-8 Dosing

physiologic secretion|research-dependent

Nafarelin Dosing

200 mcg intranasal twice daily|0.4 mg/day intranasal|protocol-based suppression cycles

Cholecystokinin-8 Side Effects

  • abdominal cramping
  • nausea
  • biliary contraction

Nafarelin Side Effects

  • nasal irritation
  • hot flashes
  • headache

Research Overview

Cholecystokinin-8

CCK-8 is a canonical gut hormone fragment with extensive documentation in digestive physiology and appetite control. Sulfation of the tyrosine residue is important for high-affinity receptor activity.

Nafarelin

Nafarelin has a long history in reproductive medicine, especially for endometriosis and cycle suppression. Studies show it down-regulates the HPG axis after an initial stimulatory flare.

Ready to buy?

Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.

Common Stacking Partners

Cholecystokinin-8 stacks with:

gallbladderpancreassatiety

Nafarelin stacks with:

FSHhCG
gut-hormonesatiety-peptideendocrine-peptideGnRH-agonistfertilityendocrinology